MediciNova, Inc. — Q1 2015 Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a development-stage biopharmaceutical company focused on small-molecule therapeutics for serious diseases with unmet medical needs. Its principal programs include MN-166 for neurological disorders, MN-001 for fibrotic diseases, MN-221 for acute asthma exacerbations, and MN-029 for solid tumors. The filing covers the unaudited quarter ended March 31, 2015, compared with the quarter ended March 31, 2014.
Key Financial Metrics
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research, development and patent expense | $0.7 million | $0.7 million |
| General and administrative expense | $1.5 million | $1.6 million |
| Total operating expenses | $2.2 million | $2.4 million |
| Operating loss | $2.2 million | $2.4 million |
| Net loss applicable to common stockholders | $2.2 million | $2.4 million |
| Basic and diluted loss per share | $0.09 | $0.10 |
| Net cash used in operating activities | $3.2 million | Net cash provided of $4.8 million |
| Cash and cash equivalents at period end | $9.1 million | $14.8 million |
Margins are not meaningful because the company reported no revenue. The filing does not disclose conventional interest-bearing debt; liabilities primarily consisted of accounts payable, accrued expenses, deferred rent, deferred taxes, and deferred revenue. Total liabilities were $4.5 million at March 31, 2015, compared with $5.3 million at December 31, 2014.
Working capital was $9.5 million at March 31, 2015. Management stated that available working capital was expected to fund operations through March 31, 2016, but cautioned that it might not support all planned research and development programs.
Material Changes Versus the Prior Comparable Period
- Operating expenses declined by approximately $149,000, or 6%, primarily because general and administrative expense decreased by approximately $121,000.
- General and administrative expense included a $100,000 vendor payment for manufactured drug product inadvertently destroyed by the vendor.
- Research, development and patent expense was substantially unchanged at approximately $0.7 million.
- Net loss improved by approximately $137,000, while loss per share improved from $0.10 to $0.09, partly reflecting a higher share count.
- Operating cash flow changed from a $4.8 million inflow in Q1 2014 to a $3.2 million outflow in Q1 2015. The prior-year inflow included collection of a $6.0 million receivable.
- Financing cash inflow declined from $3.3 million to $0.6 million. During Q1 2015, the company sold 180,000 shares under its at-the-market facility for gross proceeds of $0.7 million and net proceeds of $0.6 million.
- Common shares issued and outstanding increased to 24,637,921 at March 31, 2015 from 24,436,317 at December 31, 2014.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects substantial net losses for the next several years as it develops existing programs and potentially expands or acquires additional programs.
- The company expects to pursue additional financing through equity sales, strategic initiatives, partnerships, or other transactions. It stated that outstanding warrants could provide approximately $11.9 million of gross proceeds if exercised, although exercise is not assured.
- Subsequent to March 31, 2015, the company sold 45,000 shares for net proceeds of approximately $0.2 million and received gross proceeds of approximately $0.7 million from the exercise of 197,500 warrants.
- As of March 31, 2015, the company had no revenue and remained dependent on capital markets, partnerships, grants, and potential licensing arrangements to finance development.
- The company’s 50% investment in Zhejiang Sunmy is accounted for under the equity method. No sublicense agreement for MN-221 had been executed, and there was no assurance that the joint venture would advance MN-221 development in China.
- Goodwill of $9.6 million and in-process research and development of $4.8 million were subject to impairment considerations. No impairment charge was reported in the filing.
- No material legal proceedings or material changes to previously disclosed risk factors were reported.
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level, with no material change in internal control over financial reporting.
Important Facts for Investors to Verify
- Cash runway relative to the company’s ongoing clinical development spending and its stated ability to fund operations through March 31, 2016.
- Future equity issuance under the $10 million at-the-market facility and the resulting dilution.
- Exercise or expiration of outstanding warrants, including the 2,576,500 warrants expiring in March 2016.
- Clinical, regulatory, and partnering progress for MN-166 and MN-001, the company’s principal strategic programs.
- Status of the Zhejiang Sunmy joint venture and any future MN-221 sublicense.
- Potential impairment of goodwill and in-process research and development if development prospects deteriorate.
- Whether the $100,000 vendor payment represents a nonrecurring benefit and how future general and administrative expenses compare without it.